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Intestinal microbial metabolites are conjectured to
affect mucosal integrity through an incompletely
characterized mechanism. Here we showed that
microbial-specific indoles regulated intestinal barrier
function through the xenobiotic sensor, pregnane X
receptor (PXR). Indole 3-propionic acid (IPA), in the
context of indole, is a ligand for PXR in vivo, and
IPA downregulated enterocyte TNF-a while it upre-
gulated junctional protein-coding mRNAs. PXR-
deficient (Nr1i2/) mice showed a distinctly ‘‘leaky’’
gut physiology coupled with upregulation of the
Toll-like receptor (TLR) signaling pathway. These
defects in the epithelial barrier were corrected in
Nr1i2/Tlr4/ mice. Our results demonstrate that
a direct chemical communication between the intes-
tinal symbionts and PXR regulates mucosal integrity
through a pathway that involves luminal sensing and
signaling by TLR4.
INTRODUCTION
Intestinal luminal contents (e.g., bacteria, food, metabolic by-
products) are known to influence the gut barrier function through
immune recognition (Clemente et al., 2012; Salzman, 2011).
However, specific effects of microbial luminal metabolites on
regulating epithelial innate immune homeostasis (e.g., epithelial
barrier function) is incompletely characterized (Ashida et al.,
2012). Indeed, disruption of epithelial barrier function is now
emerging as an important mediator of intestinal inflammation
(e.g., inflammatory bowel disease) (Fasano and Shea-Donohue,296 Immunity 41, 296–310, August 21, 2014 ª2014 Elsevier Inc.2005; Maloy and Powrie, 2011; Xavier and Podolsky, 2007) as
well as organ pathophysiology (e.g., allergy, diabetes, obesity,
heart disease, arthritis, cognitive defects) (Gummesson et al.,
2011; Islam and Luster, 2012; Mayer, 2011; Meier and Plevy,
2007; Turner, 2009).
Given that there are approximately 100 trillion bacteria in the
intestines, their metabolic by-products and chemical repertoire
are likely to be important mediators of yet-to-be-defined host
phenotype (Rath and Dorrestein, 2012). Indeed, although dietary
constituents have been shown to regulate barrier function,
discrete mechanisms of microbial metabolites that regulate in-
testinal epithelial integrity remain elusive (Leavy, 2011). Because
adopted orphan nuclear receptors are known signaling interme-
diates for certain host-bacterial metabolites (e.g., bile acids and
farnesoid x receptor [FXR], dietary ligands and aryl hydrocarbon
receptor [AhR]), we focused on pregnane X receptor (PXR),
because its promiscuous ligand binding pocket might well be
capable of accommodating diverse small bacterial metabolites
(Watkins et al., 2001).
To test the hypothesis that elements of the host environment
(i.e., symbiotic bacteria) regulate intestinal barrier function
through PXR, we focused on exploring the functions of indole
metabolites (e.g., Indole 3-propionic acid [IPA]), that are exclu-
sively produced by intestinal commensal microbes (Wikoff
et al., 2009). In mice, IPA synthesis appears linked to the intesti-
nal commensal Clostridium sporogenes (Wikoff et al., 2009). In
humans under homeostatic conditions, blood IPA and indole
concentrations remain in micromolar and millimolar range,
respectively, with intestinal concentrations predicted to be
much higher (Bansal et al., 2010). To date the cellular target of
IPA remains elusive. To determine whether IPA could potentially
regulate intestinal barrier function through PXR, we performed a
combination of in vitro, ex vivo, and in vivo studies of the effect
of IPA on epithelial permeability and inflammation. The results
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physiologic ligand for PXR and downregulated enterocyte-medi-
ated inflammatory cytokine tumor necrosis factor-a (TNF-a)
while upregulating junctional protein-coding mRNAs. PXR-defi-
cient (Nr1i2/) mice exhibited a distinctly ‘‘leaky’’ intestinal
epithelium pathology, whereas replacing PXR using bone
marrow chimeras established that PXR must be present in non-
hematopoietic compartments for normal intestinal inflammatory
signals and barrier functions. Importantly, Nr1i2/ intestinal
cells exhibited upregulation of toll-like receptor 4 (TLR4). These
molecular events, as well as overall defects in the epithelial
barrier, were corrected in Nr1i2/Tlr4/ mice. Collectively,
these results demonstrate that a direct chemical communication
between the gastrointestinal symbionts and a specific nuclear
receptor pathway control mucosal homeostasis.
RESULTS
Symbiotic Intestinal Bacteria-Derived IPA Regulates
Intestinal Permeability and Inflammation through PXR
To simulate in vivo homeostatic conditions, we activated PXR
using a combination of indole with its respective metabolites.
Although IPA alone was a weak human PXR (hPXR) agonist
(EC50 120 mM, Emax 6.38-fold over control) (Figure 1A), IPA in
combination with indole significantly activated hPXR (Figure 1B).
Similar results were observed with indole 3 acetic acid (IAA) (Fig-
ure S1A available online) and supported by in silico docking
studies (Figures S1B and S1C; Table S1). In contrast, mouse
PXR (mPXR) was potently activated by IPA (EC50 0.55 mM,
Emax 18.84-fold over control) in vitro (Figure 1A) and induced
PXR target gene transcription in vivo (Figures 1C and S1D).
More importantly, although specific indoles have been shown
to activate the AhR (Denison and Nagy, 2003), we were unable
to demonstrate activation of AhR by IPA (Figure S1E).
We next examined effect of indoles on enterocyte inflamma-
tory signals and barrier function. Importantly, differences be-
tween Nr1i2/ and Nr1i2+/+ mice were maintained when
specifically assaying small intestinal permeability in vivo (Figures
S1F and S1G) as well as using an in vivo multiphoton intravital
microscopy (Figure S1H and Movies S1 and S2).
For critical validation of the ex vivo experiments demonstrating
IPA effects on junctional regulators, we coadministered C. spor-
ogenes to germ-free mice in the presence or absence of
L-tryptophan (Figure 1D). We verified that C. sporogenes inocu-
lation led to production of IPA in vivo (thus, it was assumed that
indoles were present) (Figure 1E). Germ-free mice exposed to
C. sporogenes had a significant reduction in FITC-dextran recov-
ery from the serum and this was further reduced in the presence
of L-tryptophan dosing (Figure 1F). The mice intestinal mucosa
exposed to C. sporogenes demonstrated significant induction
of PXR target genes (Mdr1,Cyp3a11,Ugt1a1), which was further
augmented in the presence of L-tryptophan (Figure 1G).
IPA Regulates Intestinal Inflammation through PXR
To validate that IPA was driving the anti-inflammatory response
in vivo directly via PXR, we exposed intestinal commensal-
depleted Nr1i2+/+ and Nr1i2/ mice to live or heat-killed
C. sporogenes. All mice were subsequently exposed to indo-
methacin (Figure 2A). We verified that only live C. sporogenes,but not the heat-killed bacterial inoculation, led to production
of IPA in vivo (Figure 2B). There was a significant reduction in
the histologic injury and in mucosal myeloperoxidase (MPO)
enzyme activity in Nr1i2+/+, but not in Nr1i2/, mice (Figures
2C and 2D). Furthermore, in these mice, intestinal mucosa
exposed to the C. sporogenes had significant induction of PXR
target gene (Ugt1a1) when compared to mice exposed to the
heat-killed strain (Figure 2E). No such effects were observed in
Nr1i2/ mice (Figures 2B–2E).
The effects of C. sporogenes in vivo were directly validated
using IPA administration by the oral route in both Nr1i2+/+
and Nr1i2/ mice. Although IPA effects could be non-target
dependent based on the concentrations administered (i.e.,
nonspecificity of molecular targets based on the concentration
of IPA), we chose to study at fixed dose of IPA using an inflam-
mation-based barrier defect (indomethacin) model. In this
model, Nr1i2+/+ and Nr1i2/ mice were administered IPA
followed by indomethacin, and intestinal permeability was
assessed. The rationale was that a defect in permeability was
required in order to show the effect of IPA in both the wild-type
and Nr1i2/ mice. IPA dosing significantly reduced FITC-
dextran permeability in Nr1i2+/+ (Figure 2F), but not in Nr1i2/
(Figure 2G), mice.
In an in vivo model of 3-deoxy-D-manno-octulosonic acid
(KDO2)-lipid A (TLR4 ligand) intubation, which elicits inflamma-
tory signals without disrupting the intestinal tissue architecture
(see Experimental Procedures), there was no overt histologic
evidence of inflammation (Figure S2A). However, TNF-a mRNA
(Figure S2B), p38-MAPK phosphorylation (Figure S2C), and
permeability to FITC-dextran (Figure S2D) were clearly induced
after KDO2 treatment. In this model, at IPA concentrations that
were achievable through oral gavage (Figure S2E), we found
that IPA notably decreased TNF-a mRNA expression more in
the Nr1i2+/+ mice (3.73-fold) intestinal epithelium relative to
Nr1i2/ mice (1.72-fold) (Figure S2F). Together, these studies
and the effects of IPA depletion in vivo (see Table S2; Figures
S2G–S2I) establish PXR as an important enterocyte target of IPA.
Nr1i2–/– Mice Exhibit Enhanced Ultrastructural Defects
that Directly Correlate with Increased Intestinal
Permeability and Xenobiotic Toxicity
To study the function of PXR under steady-state conditions, we
performed detailed histological analysis using 6- to 8-week-old
Nr1i2/ and Nr1i2+/+mouse intestines. Although gross features
appeared unchanged, histological examination of the mucosa of
Nr1i2/ mice small intestines showed significant diminution of
the villus-crypt ratio (Figure S3A), marked neutrophil infiltration,
and increased MPO enzyme activity (Figure S3B). The data
shown compare the jejunum (highest expression of PXR in the in-
testine) ofNr1i2+/+ andNr1i2/mice; data pertaining to other re-
gions (i.e., duodenum, ileum) have similar trends (data not
shown). Although subtle, these differences indicate that the
small intestine of Nr1i2/ mice might persist in a state of mild
elevated stress that might culminate as overt inflammation
when exposed to injurious insults. Indeed, we did not observe
any significant changes in unfolded protein response (UPR)
genes (UPR RT2 ProfilerPCR Array, SABiosciences); however,
a single gene, Serp1 mRNA, was induced 27-fold in Nr1i2/
as compared with Nr1i2+/+ mouse intestinal mucosa (data notImmunity 41, 296–310, August 21, 2014 ª2014 Elsevier Inc. 297
Figure 1. Commensal-Derived Indole Metabolite, IPA, Regulates PXR Activation
(A) Transcriptional activity of a PXR reporter gene (multidrug-resistance-associated protein 2 orMRP2 luciferase) cotransfectedwithmPXR (black) and hPXR (red)
expression plasmids in 293T cells following treatment with IPA (n = 3). Abbreviation: RLU, relative light unit.
(B) Transcriptional activity of a PXR reporter gene (MRP2 luciferase) cotransfected with hPXR expression plasmid in 293T cells following treatment with fixed
concentration of indole (1mM) and increasing concentrations of IPA (n = 3). Abbreviation: RLU, relative light unit. Data expressed as fold change in RLU compared
to vehicle (DMSO) controls.
(C) Real-time qPCR analysis ofMdr1 expression inNr1i2+/+ andNr1i2/mice jejunum villi enterocytes following oral treatment with IPA (20mg/kg/day) (n = 5 per
group). *p% 0.0001; **p% 0.001; n.s., not significant (two-way ANOVA with Tukey’s multiple comparison test).
(D) Schematic of germ-free mouse treatment schedule. Six treatment groups are shown by color code: Swiss Webster Germ Free mice (SWGF) group,
administered 100 ml LB and 100 ml sterilized water by oral gavage; SWGF + tryptophan (Trp) group, administered 100 ml LB + L-tryptophan; SWGF + Heat-killed
C. sporogenes (C.s) group, administered C.s by oral gavage; SWGF + C.s group, administered C.s by oral gavage; SWGF + Heat-killed C.s + Trp group; and
SWGF + C.s + Trp group, administered C.s and Trp by oral gavage (see Experimental Procedures). All the treatments were scheduled for 6 sequential days.
(E) Plasma IPA peak area intensity values plotted by treatment group as illustrated in the schema (D). Color-coded histograms show mean ± SEM values per-
taining to each treatment group. IPA concentrations in micromoles (mM) are listed by color code.
(F) Serum FITC-dextran recovery in treatment groups illustrated in schema (D). *p% 0.0001; two-way ANOVA with Tukey’s multiple comparison test; n = 6 per
group.
(G) Real-time qPCR analysis of Mdr1, Cyp3a11, and Ugt1a1 mRNA expression in small intestinal mucosa from schema (D).
All graphs show mean values ± SEM. Also see Figure S1, Table S1, and Movies S1 and S2.
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glycoprotein and stabilize their signaling (e.g., TLR4) (Yamaguchi
et al., 1999). In keeping with the mild state of intestinal stress,298 Immunity 41, 296–310, August 21, 2014 ª2014 Elsevier Inc.defects observed in Nr1i2/ mice are not due to any gross
changes in proliferation (BrdU) or apoptosis (TUNEL) of the
epithelium (Figure S3C).
Figure 2. Commensal C. sporogenes Reconstitution Decreases Intestinal Permeability and Inflammation in a PXR-Dependent Manner
in Mice
(A) Schematic of commensal depletion and C. sporogenes reconstitution experiment in Nr1i2+/+ and Nr1i2/ mice (see Experimental Procedures).
(B) Plasma IPA peak area intensity values plotted by treatment groups as illustrated in the schema (A). The IPA concentrations in micromoles (mM) pertaining to
each group is illustrated above each histogram.
(C) Hematoxylin and eosin staining of C. sporogenes + L-tryptophan and heat-killed C. sporogenes + L-tryptophan exposed Nr1i2+/+ and Nr1i2/mice jejunum
cross-sections in accordance with schema (A). Scale bars represent 50 mm.
(D) Jejunal MPO activity (unit/g of total protein) in treatment groups from schema (A) as illustrated.
(E) Real-time qPCR analysis of Ugt1a1 mRNA expression in small intestinal mucosa from schema (A).
(F andG) SerumFITC-dextran recovery following oral gavage of IPA (20mg/kg/day) and indomethacin (see schematic) in (F)Nr1i2+/+ (n = 9) and (G)Nr1i2/ (n = 9)
mice.
All graphs show mean values ± SEM. *p% 0.01, two-way ANOVA with Sidak’s multiple comparison test; n = 6 per group; **p% 0.01, Student’s t test; n.s., not
significant. Also see Figure S2 and Table S2.
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Figure 3. Nr1i2–/– Mice Are More Susceptible to Toxic Injuries to the Small Intestine
(A) Hematoxylin and eosin staining of indomethacin (Indo)-treated Nr1i2+/+ and Nr1i2/ mice jejunum cross-sections.
(B) Jejunal MPO activity (unit/g of total protein) in Nr1i2+/+ and Nr1i2/ mice treated with indomethacin (n = 6 per group).
(C) Histological score measuring severity of tissue damage in jejunum from Nr1i2+/+ and Nr1i2/ mice in indomethacin-treated and untreated groups (n = 6
per group).
(D) Weight-to-length ratio of the jejunum (enteropooling) in Nr1i2+/+ and Nr1i2/ mice treated with anti-CD3 antibody. The change in weight-to-length ratio in
Nr1i2+/+ and Nr1i2/ mice exposed to anti-CD3 was 27.6% and 22.9%, respectively. Values represent mean ± SEM (n = 5 per group).
(E) Hematoxylin and eosin staining of anti-CD3 antibody-treated Nr1i2+/+ and Nr1i2/ mice jejunum cross-sections.
(legend continued on next page)
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insults, we subjected Nr1i2/ and Nr1i2+/+mice to four toxic in-
testinal injury models. In the indomethacin-induced (85 mg/kg
body weight, i.p., single dose) small intestine inflammation
model, the Nr1i2+/+ mice exhibited modest inflammation by his-
tology (Figure 3A) and in jejunal MPO activity (Figure 3B). In
contrast, theNr1i2/mice showed significantly enhanced basal
MPO activity, which increased upon indomethacin treatment
(Figure 3B). In evaluating the histology in Nr1i2/mice, the his-
tologic score increased by 6.2-fold over that observed inNr1i2+/+
mice (Figure 3C). In the anti-CD3 antibody-induced intestinal
inflammation-edema model, mice were exposed to anti-CD3
(clone 2C11, 200 mg i.p.) and tissues were harvested 3 hr later
for enteropooling. Notably, 100% of Nr1i2/ mice given this
dose of anti-CD3 antibody succumbed to intestinal edema and
died within 72 hr of dosing. Indeed, small bowel isolated after
24 hr of dosing with anti-CD3 antibody showed that the mean
values of enteropooling did not exceed 30 mg/cm (maximum
value obtained 31.5 mg/cm), suggesting that enteropooling
values saturate at 30–31 mg/cm (Musch et al., 2002). Although
the changes in enteropooling values were not significantly
different, it is clear that the Nr1i2/ mice have increased
susceptibility to anti-CD3-mediated injury based on the observa-
tion that the mean enteropooling values have maximized
29.5mg/cm (maximum value31.5mg/cm) (Figure 3D). There-
fore, the true increase in enteropooling is capped by saturated
values in the anti-CD3-treated Nr1i2/ mice. In addition, there
was near-complete blunting of crypt-villus architecture in
Nr1i2/ as compared toNr1i2+/+mice (Figure 3E). In the gastro-
intestinal ischemia-reperfusion model, the endogenous lectin
complement pathway is a key initiator of intestinal inflammation
in which the intestinal epithelium plays an important role in medi-
ating such damage (Hart et al., 2005). An early finding that per-
sists and then worsens with prolonged ischemia reperfusion is
intestinal barrier dysfunction as manifested by changes in intes-
tinal permeability (Hart et al., 2005). We assessed FITC-dextran
recovery after oral gavage of Nr1i2+/+ and Nr1i2/ mice. The
change in permeability as assessed by a change in recovery of
mean levels of FITC-dextran in the serum of mice for Nr1i2+/+
and Nr1i2/ mice was 193% and 488.9% (Figure 3F), respec-
tively. These results suggest that the Nr1i2/ mice are sig-
nificantly more susceptible to ischemia-reperfusion-mediated
changes in intesinal barrier function. Finally, we used an endo-
toxic shock model, whereby systemic LPS induces a sepsis-
like syndrome that prominently features intestinal barrier
dysfunction (Roger et al., 2009). Nr1i2/ mice treated with
LPS had significantly worse survival than their Nr1i2+/+ counter-
part, suggesting that the loss of PXR significantly worsens sur-
vival in LPS-mediated septic syndrome, in which intestinal
dysfunction plays a major role (Figure 3G). The LPS findings
corroborate previous observations that PXR protects against
LPS-mediated liver damage (Wang et al., 2010). Together,
Nr1i2/ mice demonstrate heightened sensitivity toward all(F) Serum FITC-dextran recovery following gastrointestinal ischemia-reperfusion i
as assessed by a change in recovery of mean levels of FITC-dextran in the serum
(G) Kaplan-Meier survival curves of Nr1i2+/+ and Nr1i2/ mice treated with LPS
All graphs show mean values ± SEM. *p% 0.02, **p% 0.0001, two-way ANOVA
Figure S3.four direct and indirect toxic intestinal injury models (Figure 3;
Clayburgh et al., 2005; Ettarh and Carr, 1996; Zhou et al.,
2006). The lack of significant steady-state gross inflammatory
pathology in Nr1i2/mice contrasts with this heightened sensi-
tivity toward xenotoxic challenge. To reconcile these findings,
we performed ultrastructural and biochemical analysis of
Nr1i2+/+ and Nr1i2/ mice jejunal epithelium. Transmission
electron microscopy (TEM) of Nr1i2/ mice intestinal epithelial
cells showed loosely packed shorter microvilli relative to
Nr1i2+/+ mice (Figures 4A and 4B). Additionally, Nr1i2/ mice
microvilli show significantly diminished digestive enzyme activ-
ities compared to Nr1i2+/+ microvilli (Figure 4C), and the activity
(Figure 4D) and abundance (Figure 4E) of alkaline phosphatase is
also notably reduced in the Nr1i2/ mice intestine. Together,
these data demonstrate that key aspects of the fine structure
and enzyme expression in the Nr1i2/ mice intestine would
explain its enhanced sensitivity toward xenobiotic challenge
(Matsui et al., 2011).
We next examined the cell-cell junctional complex, an essen-
tial structural component of the epithelial barrier. TEM showed
that the tight-junction (Tj) and adherens-junction (Aj) complex
(black arrow) in Nr1i2/ mice intestinal epithelium was signifi-
cantly more electron dense, diffuse with dense interconnected
stranding (Figure 4F). The mRNA expression of these key
junctional-complex markers were markedly diminished in the
Nr1i2/ mice, except Claudin-2, which is known to induce bar-
rier defects (Figure 4G; Van Itallie and Anderson, 2006). Immuno-
fluorescence showed similar trends (Figures S4A and S4B).
Furthermore, in comparison with Nr1i2+/+ mice, there is
increased FITC-dextran recovery in serum (Figure 4H). Together,
these ultrastructural and functional assays implicate PXR as a
physiologic regulator of intestinal barrier function.
TLR4 Signaling Is an Essential Causative Pathway in the
Epithelial Barrier Defects Observed in the Nr1i2–/– Mice
To screen for molecular mechanisms that are responsible for
barrier dysfunction in Nr1i2/ mice, we determined relative
abundance of key host mRNAs encoding proteins involved in
inflammation and microbial invasion. We performed real-time
qPCR for anti-inflammatory, antimicrobial, and proinflammatory
markers using total RNA isolated from Nr1i2+/+ and Nr1i2/
mice villi enterocytes. In the Nr1i2/ mice, there is a significant
downregulation of mRNAs involved in anti-inflammatory and
antimicrobial function, along with a concomitant increase in
proinflammatory cytokine mRNAs (Figure 5A). Given that TLRs
are critical regulators of intestinal barrier function as well as
inflammation, we chose to focus on them (Asquith and Powrie,
2010). We performed real-time qPCR for all ten mammalian
(mouse) TLRs. TLR overexpression was modest (1.2- to 1.8-
fold) and variable (Figure 5B); however, downstream TLR
pathway kinase activation was enhanced in Nr1i2/ mice (Fig-
ure S5A). Among the TLRs, TLR2 and TLR4 are expressed on
the villi enterocytes and play significant roles in the regulationnjury inNr1i2+/+ andNr1i2/mice (n = 5 per group). The change in permeability
of Nr1i2+/+ and Nr1i2/ mice was 193% and 488.9%, respectively.
(n = 6 per group).
with Tukey’s multiple comparison test. Scale bars represent 50 mm. Also see
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Figure 4. Ultrastructural and Functional Defects in Nr1i2–/– Mice Small Intestine
(A and B) Representative TEM images ofNr1i2+/+ (A) andNr1i2/ (B) mice jejunum shows loose packing of microvilli inNr1i2/mice. g represents packing angle
between adjacent microvilli. Packing of microvilli in Nr1i2+/+ and Nr1i2/ mice jejunum was quantified by assessing the packing angle (g) between adjacent
microvilli. g inNr1i2/mice cross-sections (81.0 ± 23.6, n = 273) is significantly higher andmore variable compared toNr1i2+/+mice (59.6 ± 7.0, n = 275) (n = 5
per group).
(C) Sucrase, maltase, lactase, and dipeptidyl peptidase (DPPIV) enzyme activities inNr1i2+/+ andNr1i2/mice jejunum villi enterocytes. Proportionality between
amount of enzyme present (jejunal villi enterocyte homogenate containing 20 mg/ml of protein as enzyme, x axis) and amount of substrate liberated (optical
density, y axis) in 60 min was plotted in the graph (n = 8–10 per group).
(D) Alkaline phosphatase enzyme activity in Nr1i2+/+ and Nr1i2/ mice jejunum villi enterocyte homogenate (n = 8–10 per group).
(E) Immunoblot analysis of alkaline phosphatase and b-actin (loading control) in Nr1i2+/+ and Nr1i2/ mice jejunum villi enterocytes (n = 5 per group).
(legend continued on next page)
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TLRs that might affect inflammatory-cytokine-mediated barrier
function in Nr1i2/ mice, we incubated Nr1i2/ enterocytes
ex vivo with TLR2 and TLR4 inhibitors. TLR2 inhibition in-
creased TNF-a and IL-6 mRNA expression in the intestinal
mucosa of Nr1i2/ mice; conversely, TLR4 inhibition signifi-
cantly suppressed cytokine mRNA expression (Figure S5B).
Furthermore, we generated Nr1i2/Tlr2/ mice and mucosa
extracted from these mice show increased TNF-a and IL-6
mRNA expression when compared to Nr1i2/ (Figure S5C).
These findings correlate with the observation that the loss of
Tlr2 in Nr1i2/ mice increased intestinal permeability (Figures
S5D–S5F).
We focused next on TLR4 because it is a critical determinant of
LPS signaling in the intestine (Abreu et al., 2001). The basal
expression of TLR4 protein was modestly elevated (1.8-fold)
inNr1i2/ (Figure 5C) and we also observed an inverse relation-
ship between Pxr and Tlr4 mRNA expression in an intestinal cell
line, Caco-2 (data not shown), and primary human intestinal
mucosa (data not shown). To study the role of TLR4 in barrier
dysfunction in Nr1i2/ mice, we crossed the Nr1i2/ with
Tlr4/ mice. In comparison with Nr1i2/ mice, the abundance
of mRNAs encoding key Tj, Aj proteins, and pro- and anti-inflam-
matory cytokines were reversed in Nr1i2/Tlr4/ mice epithe-
lium to levels comparable to those observed in Nr1i2+/+ mice
(Figure 5D).
Because thesemarkers encode for proteins involved in epithe-
lial junctional complex formation and inflammation, we speculate
that TLR4 is indeed responsible for the barrier dysfunction
observed in Nr1i2/ mice. To validate this hypothesis, we as-
sessed whether the magnitude of TNF-a mRNA expression
and FITC-dextran permeability was Tlr4 gene-dose dependent.
We generated Tlr4 heterozygotes (at least 50% reduction in
protein) in Nr1i2/ mice background (data not shown). Entero-
cyte TNF-a mRNA expression and FITC-dextran recovery had
similar quantitative reduction (Figures S5G and S5H). To further
validate our observations regarding genes encoding junctional
complex proteins, we performed TEM and immunofluorescence
studies. The Nr1i2/Tlr4/ mice have microvilli lengths that
were larger thanNr1i2/mice and comparable to that observed
in Nr1i2+/+ mice (Figure 5E). Indeed, the same trend was
observed in the ultrastructure of the junctional complex (Fig-
ure 5F) and immunofluorescence staining for Zo-1 and E-cad
(Figures S5I and S5J). The activities of brush border enzymes
(Figure 5G) and FITC-dextran permeability (Figure 5H) in the
Nr1i2/Tlr4/ mice was also similar to that observed in
Nr1i2+/+ mice. Additionally, Nr1i2/Tlr4/ mice displayed
significantly attenuated damage response to indomethacin
(Figures 6A and 6B). Together, these studies show that Tlr4 is
essential to maintain epithelial barrier defects observed in the
Nr1i2/ mice.(F) Representative TEM images of Nr1i2+/+ and Nr1i2/mice jejunum enterocyte
condensation. Inset shows magnified views of cell-cell junctional complex.
(G) Real-time qPCR analysis of key Tj and Aj regulatory genes in Nr1i2+/+ and Nr
change in Nr1i2/ mice relative to mRNA levels in Nr1i2+/+ mice.
(H) Serum FITC-dextran recovery in Nr1i2+/+ and Nr1i2/ mice following treatm
All graphs show mean values ± SEM. *p % 0.0001; **p % 0.0001; n.s., not sig
represent 0.5 mm (A, B, and F). Also see Figure S4.IPA Protects against Indomethacin-Induced Intestinal
Injury via PXR and TLR4
To further validate the requirement for TLR4 as a critical determi-
nant of the effects of microbiota-derived PXR ligand IPA, Tlr4+/+
and Tlr4/mice were exposed to IPA followed by indomethacin
(as previously described for experiments with Nr1i2+/+ and
Nr1i2/ mice). The results demonstrate that the presence of
Tlr4 is required for IPA-induced changes in permeability defects
induced by indomethacin (i.e., IPA significantly reduces FITC-
dextran permeability induced by indomethacin) (Figure 6C).
Indeed, to directly validate that the entire loop driven by micro-
biota-derived IPA results from modulation of TLR4, which in
turn regulates intestinal permeability, Nr1i2+/+ mice were
commensal depleted for 15 days and/or followed by exposure
to TLR4 ligand, KDO2, and/or IPA delivered orally (Figure 6D).
The results demonstrate that commensal depletion increased in-
testinal permeability, which was further worsened by 2.8-fold
with the addition of the TLR4 ligand KDO2. Note that in conven-
tional Nr1i2/mice possessing intact intestinal microbiota (i.e.,
LPS), the FITC-dextran recovery in blood was 856 mg/ml (Fig-
ure 4H), which is actually lower than commensal-depleted
Nr1i2+/+ mice exposed to KDO2 (1,495 mg/ml) (Figure 6D). In
commensal-depleted Nr1i2+/+ mice, reconstitution of mice with
IPA results in a significant decrease in permeability. These re-
sults further validate our hypothesis that loss of microbiota pro-
ducing IPA can induce a Nr1i2/-like (not identical) state,
whereby the presence of a TLR4 ligand, KDO2, worsens intesti-
nal permeability and is corrected only when IPA is reconstituted
in Nr1i2+/+ mice (Figure 6D), but not in Nr1i2/ mice (Figures
2F and 2G).
Finally, to understand whether the initial signals leading to
disruption of the epithelial barrier originates via hematopoietic
or nonhematopoietic cells (e.g., predominantly the epithelium),
we performed bone marrow chimera experiments between
Nr1i2/ and Nr1i2+/+ mice. These studies clearly show that
immune reconstitution with either Nr1i2+/+ or Nr1i2/ hemato-
poietic cells have no effect on proinflammatory markers and in-
testinal permeability to FITC-dextran (Figures 7A–7C). Indeed,
because intestine-homing hematopoietic-derived cells aremajor
source of cytokines that disrupt barrier function (e.g., TLR4
signaling), it should be stated that PXR negatively regulates
TLR4 bone-marrow-derived macrophages or mononuclear cells
(data not shown). We saw no changes in serum FITC-dextran re-
covery, TNF-a, or IL-6 mRNA in Nr1i2+/+ and Nr1i2/ mice
transplanted with either Nr1i2/ or Nr1i2+/+ bone marrow,
respectively (Figures 7A–7C). In order to further determine
whether there was any contribution by TLR4 signals emanating
from hematopoietic-derived cells within the intestine, we derived
combinatorial chimeric strains harboring loss or gain of TLR4
protein in these cells resident in Nr1i2+/+ or Nr1i2/ mice.
Nr1i2+/+ mice harboring either a gain or loss of TLR4 protein ins demonstrating cell-cell junctional complexes and perijunctional cytoskeletal
1i2/ mice jejunum villi enterocytes (n = 8–10 per group). Data plotted as fold
ent with KDO2 (n = 8–10 per group).
nificant; two-way ANOVA with Tukey’s multiple comparison test. Scale bars
Immunity 41, 296–310, August 21, 2014 ª2014 Elsevier Inc. 303
(legend on next page)
Immunity
Bacterial Metabolites Regulate Enterocyte Function
304 Immunity 41, 296–310, August 21, 2014 ª2014 Elsevier Inc.
Immunity
Bacterial Metabolites Regulate Enterocyte Functionbone-marrow-derived cells within the intestine (LP cells) showed
similar levels of serumFITC-dextran recovery aswell as TNF-a or
IL-6 mRNA, respectively. Nr1i2/mice expressing nonhemato-
poietic TLR4 and harboring either a gain or loss of TLR4 protein
in bone-marrow-derived cells within the intestine (LP cells)
showed no significant difference in serumFITC-dextran recovery
or TNF-a or IL-6 mRNA levels. Similar results were obtained in
Nr1i2/ mice with loss of nonhematopoietic TLR4 and
harboring either a gain or loss of TLR4 protein in bone-
marrow-derived cells within the intestine (LP cells) (Figures 7D
and 7E). This effectively shows that bone-marrow-derived
TLR4, a major LPS-responsive effector of TNF-a, is unable to
alter the intestinal phenotype induced by nonhematopoietic tis-
sue. Thus, PXR resident in the nonhematopoietic compartment
(i.e., epithelium) is important in dictating the initial response to
external cues inciting epithelial barrier dysfunction.
DISCUSSION
The regulation of the intestinal barrier by intestinal commensal
bacteria has been alluded to in several important reviews on
this topic (Abreu, 2010; Salzman, 2011; Wells et al., 2011). How-
ever, thus far few discrete mechanisms have emerged (Abreu,
2010; Chen et al., 2010; Kelly et al., 2004; Patel et al., 2012).
Our data support the role that PXR is an essential regulator of in-
testinal barrier effects under conditions of homeostasis. The four
models of bowel injury, as well as evidence of chronic subclinical
inflammation under basal conditions (Zhou et al., 2006), sug-
gests that PXR is an essential modifier of innate immunity in
the intestine and its response to xenobiotic injury. Both of these
elements can be tied to intestinal barrier function, which is clearly
aberrant in Nr1i2/mice (Matsui et al., 2011; Zhou et al., 2006).
Bone marrow chimera studies indicate that neither Nr1i2+/+ or
Nr1i2/ bone marrow alters expression of TNF-a, IL-6, and
FITC-dextran recovery in mice of the opposite genotype, which
strongly indicates that PXR expression in the nonhematopoietic
compartment determines the epithelial phenotype. Because
PXR is expressed predominantly in epithelial and not mesen-
chymal cells (Bookout et al., 2006), it is logical to conclude that
the state of activation of epithelial PXR is paramount in deter-
mining the initial events leading to the observed intestinal barrier
phenotype. Indeed, villus expression of PXR within the intestinal
mucosa puts this receptor in nearest contact with the bacterial
commensals in the lumen. A notable caveat in our experimentsFigure 5. Small Intestine Epithelial Barrier Dysfunction in Nr1i2–/– Mice
(A and B) Real-time qPCR analysis of (A) anti-inflammatory, antimicrobial, proinfla
enterocytes (n = 8–10 per group). Data plotted as fold change in Nr1i2/ mice r
(C) Immunoblot shows increased expression of TLR4 in Nr1i2/mice (n = 6 per g
Quantitation of band density was performed with two blots each with three diffe
(D) Real-time qPCR analysis of key regulatory genes of epithelial barrier function i
(n = 8–10 per group).
(E) Representative TEM images of Nr1i2+/+, Nr1i2/, Tlr4/, and Nr1i2/Tlr4/
length (right).
(F) Representative TEM images of Nr1i2+/+, Nr1i2/, Tlr4/, and Nr1i2/Tlr4/
(G) Enzyme (as denoted) activity assays performed with jejunal villi enterocyte ho
expressed as fold change relative to Nr1i2+/+ mice.
(H) Serum FITC-dextran levels in Nr1i2+/+, Nr1i2/, Tlr4/, and Nr1i2/Tlr4/
All graphs showmean values ± SEM. *p% 0.05; **p% 0.01; n.s., not significant; tw
(H) or Student’s t test in (C). Scale bars represent 0.5 mm in (E) and (F). Also seewas that in order to demonstrate the plausibility that indoles
would have a physiologic target in vivo, we performed all our
experiments using ex vivo systems (i.e., intestinal tissues incu-
bated in OLA rather than in vivo administration). These experi-
ments were performed ex vivo to circumvent the inherent
problem associated with a perfect drug like OLA (PubChem,
ST093573), which will probably be absorbed almost completely
by mucosal surfaces, thus precluding efficient luminal delivery.
In this context, germ-free mice (either gnotobiotic or axenic)
would not be ideal experiments because only specific gut bacte-
ria produce indoles and its metabolites (e.g., C. sporogenes in
mice) (Wikoff et al., 2009). The exact species producing indoles
and its metabolites in humans remain unknown; however,
C. sporogenes is a soil bacterium present in humans and
germ-free mice replete with this bacterium do show alterations
in intestinal barrier function. Indeed, these results are consistent
with and extend prior observations that germ-free mice reconsti-
tuted with conventional intestinal microbes significantly increase
liver PXR and its target gene, Cyp3a11, expression (Claus et al.,
2011). We have performed microbial reconstitution experiments
in commensal-depleted mice that have validated our ex vivo
observations that bacterial indoles (in particular IPA) directly
affect intestinal barrier properties in vivo through actions medi-
ated via PXR.
Our data implicate epithelial PXR as a central regulator of
TLR4-mediated control of the intestinal barrier function. This
regulation is intrinsically associated with intestinal commensals,
specifically those involved with the metabolism of tryptophan
and production of indoles and specific metabolites (i.e., IPA).
We hypothesize that this association is tightly regulated to
ensure ‘‘fine-tuning’’ of TLR4 expression in the intestine at levels
appropriate to the abundance of LPS and perhaps other micro-
bial-derived ligands. For homeostasis, all three components of
this system (indole-secreting intestinal commensals, epithelial
PXR expression, and TLR4) must be at appropriate levels for a
given host—a lack of IPA or PXR or an excess of TLR4 can
lead to intestinal barrier dysfunction. In fact, compromised intes-
tinal barrier function has been implicated in the pathogenesis of
several disease states (e.g., type I diabetes, asthma, autism,
acne, allergies, etc.) including inflamatory bowel disease (IBD)
(Gummesson et al., 2011; Islam and Luster, 2012; Mayer,
2011; Meier and Plevy, 2007; Turner, 2009). Hence, search for
effective treatment options to prevent intestinal epithelial barrier
defects may have broader implications beyond IBD.Requires TLR4 Expression and Signaling
mmatory, and (B) Tlr gene expression inNr1i2+/+ andNr1i2/mice jejunum villi
elative to mRNA levels in Nr1i2+/+ mice.
roup) (left). Immunoblots are representative of three independent experiments.
rent exposure times (right).
n Nr1i2+/+, Nr1i2/, Tlr4/, and Nr1i2/Tlr4/mice jejunum villi enterocytes
 mice jejunum showing microvilli (left) and quantitation of average microvillus
 mice jejunum showing cell-cell junctional complex.
mogenate from Nr1i2+/+, Nr1i2/, Tlr4/, and Nr1i2/Tlr4/mice. Data are
mice (n = 8–10 per group).
o-way ANOVAwith Tukey’s multiple comparison test in (A), (B), (D), (E), (G), and
Figure S5.
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Figure 6. TLR4 Is Critical for Indomethacin-
Induced Intestinal Injury as well as IPA
Effects on Permeability In Vivo
(A) Representative hematoxylin and eosin staining
of vehicle (-Indo) and indomethacin (Indo)-treated
Nr1i2/Tlr4/ mice jejunum cross-sections
(n = 6 per group).
(B) Jejunal MPO activity (unit/g of total protein) in
Nr1i2/ and Nr1i2/Tlr4/ mice treated with
indomethacin (n = 6 per group). *p% 0.005, one-
way ANOVA with Sidak’s multiple comparison
test.
(C) Serum FITC-dextran recovery following oral
gavage of IPA (20 mg/kg/day) and indomethacin
(see schematic) in Tlr/ (n = 9) mice.
(D) Serum FITC-dextran recovery following oral
gavage of IPA (20 mg/kg/day) and KDO2
200 mg/day (see schematic) in conventional mice
(Nr1i2+/+) and commensal-depleted (CD) mice
(Nr1i2+/+) (n = 8 per group).
All graphs show mean values ± SEM. *p% 0.004,
**p % 0.05; n.s., not significant; two-way ANOVA
with Tukey’s multiple comparison test.
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clear-receptor-driven pathways in intestinal immune cells that
regulate barrier function (Kelly et al., 2004; Leavy, 2011). It
adds a new dimension to recent observations that the intestinal
epithelial homeostasis is tightly orchestrated by the circadian
clock (e.g., RevErba) as well as microbiota transduced by
TLRs (Mukherji et al., 2013) and that bacterially derived uracil
serve as modulators of mucosal immunity and intestine-microbe
homeostasis in Drosophila (Lee et al., 2013). Metabolomic anal-
ysis have identified low levels of tryptophan in Il10/ mice, and
its host-derived kyneurenine metabolite levels are elevated.
These observations have led to the hypothesis that the kynure-306 Immunity 41, 296–310, August 21, 2014 ª2014 Elsevier Inc.nine metabolites might be involved in
the regulation of immune tolerance
toward intestinal microbiota by inducing
Treg cell differentiation that produce IL-
10 (Lin et al., 2010). Furthermore, plasma
tryptophan levels are reduced in patients
with Crohn’s disease (Gupta et al., 2012;
Hisamatsu et al., 2012). Interestingly,
fecal tryptophan levels are elevated in pa-
tients with Crohn’s disease, suggesting
perhaps that tryptophan metabolism is
blunted in the microbiota of these pa-
tients (Jansson et al., 2009). In keeping
with this notion of reduced tryptophan
metabolism, indoxyl sulfate (product
of indole metabolism by bacteria) is
reduced in mice exposed to DSS (Dong
et al., 2013) and IPA is significantly
reduced in the H. hepaticus colitis model
in Rag2/mice (Lu et al., 2012). Further-
more, patients with HIV infection demon-
strate an inverse correlation of serum
IPA and LPS (marker of intestinal microbi-
al translocation), supporting the view thatIPA regulates intestinal permeability in humans (Cassol et al.,
2013). These observations are consistent with the notion that
altered bacterial amino acidmetabolism correlateswith intestinal
homeostasis (Martin et al., 2008). Thus, taken together, these ob-
servations provide important chemical biology steps toward a
more comprehensive understanding of intestinal barrier function.EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
The human colon cancer cell lines (Caco-2 and LS174T) and 293T cells were
obtained from the American Type Culture Collection (ATCC) and cultured
(legend on next page)
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mental Experimental Procedures.
Mice
Tlr4/ (B6.B10ScN-Tlr4lps-del/JthJ, stock number 007227), Tlr2/ (B6.129-
Tlr2tm1Kir/J, stock number 004650), and C57BL/6J (stock number 000664)
mice were obtained from the Jackson Laboratory. Swiss Webster (SW, con-
trol) and Swiss Webster Germ Free (SWGF) mice (7–8 weeks old, female)
were purchased from Taconic. All animal experiments were approved by the
animal institute committee (protocol # 20070715, 20100711) of the Albert
Einstein College of Medicine and were performed in accordance with institu-
tional and national guidelines. For further details, see the Supplemental Exper-
imental Procedures.
Genotyping
Mouse tail DNAs were used for genotyping according to manufacturer’s in-
structions (DNeasy Blood and Tissue kit, QIAGEN). Primer sequences and
methods are in the Supplemental Experimental Procedures.
Histology and Immunofluorescence Analysis
Intestinal tissue sections (paraffin and frozen) were prepared and hematoxylin-
eosin staining was performed in the histology core facility of Albert Einstein
College of Medicine. Histological scoring was performed according to
previously published methods (Asano et al., 2009). Experimental details in
the Supplemental Experimental Procedures.
Isolation of Small Intestine Villi Enterocytes
We have employed the modified Weiser method to isolate pure villus entero-
cytes from the jejunum in all mice experiments as previously published
(Weiser, 1973). Details in the Supplemental Experimental Procedures.
Oral Dosing of IPA
Nr1i2+/+ and Nr1i2/mice were gavaged with 10, 20, and 40 mg/kg IPA, dis-
solved in sterile PBS (pH 7.4) in 100 ml volume per mice for 4 consecutive days.
Swiss Webster (SW) and Swiss Webster Germ Free (SWGF) mice were orally
gavaged with 20 mg/kg IPA for 4 consecutive days.
In Vivo Toxic Small Intestine Injury Models
For indomethacin-inducedmouse jejunitis model, we havemodified a protocol
published by Ettarh and Carr (1996) by using a single intraperitoneal dose of
indomethacin to reduce the toxicity in Nr1i2/ mice. Details in the Supple-
mental Experimental Procedures.
Lenti-Based shRNA Knockdown Systems
Details of the procedure can be found in the recent publication by our labora-
tory (Wang et al., 2011).
Statistical Analysis
Data are shown as mean ± SEM. The significance of difference was analyzed
by two-tailed Student’s t test or ANOVA with post-hoc tests as indicated. The
Kaplan-Meier method was used for survival and differences were analyzed by
the log rank test (Figure 3G). All analyses were performed using GraphPad
PRISM v.6.01 (GraphPad Software). p < 0.05 was considered statistically
significant.
Further experimental details, including in vitro transcription assay, transmis-
sion electron microscopy, enzyme activity assay, tissue myeloperoxidaseFigure 7. Epithelial Barrier Defects in Nr1i2–/– Mice Small Intestine Is D
(A and B) Real-time qPCR analysis of proinflammatory markers (A) TNF-a and (B) I
(n = 9),Nr1i2+/+BM/Nr1i2/ (n = 9),Nr1i2/BM/Nr1i2+/+ (n = 6), andNr1i2/
change in all mice groups compared to Nr1i2+/+ mice.
(C) In vivo FITC-dextran permeability assay was performed in Nr1i2+/+ (n = 10), Nr
Nr1i2/ BM/ Nr1i2+/+ (n = 6), and Nr1i2/ BM/ Nr1i2/ (n = 5) mice.
(D) Real-time PCR analysis of proinflammatory markers (blue) TNF-a and (red) IL-
expressed as fold change in all mice groups compared to Nr1i2/Tlr4+/+/ Nr1
(E) In vivo FITC-dextran permeability assay was performed in (n = 5) mice jejuna
All graphs show mean values ± SEM; n.s., not significant; two-way ANOVA with
308 Immunity 41, 296–310, August 21, 2014 ª2014 Elsevier Inc.(MPA) activity assay, in vivo intestine permeability assay, germ-free mice,
commensal depletion, real-time quantitative RT-PCR, immunoblot, tandem
mass spectrometry (LC/MS/MS), bone marrow transplantation, BrdU and
TUNEL staining, TLR2 and TLR4 inhibition experiments, and intravital imaging
of the intestines, can be found in the Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, two tables, and two movies and can be found with this article
online at http://dx.doi.org/10.1016/j.immuni.2014.06.014.
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